Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intoplicine - Sanofi Oncology

Drug Profile

Intoplicine - Sanofi Oncology

Alternative Names: NSC-645008; RP 60475

Latest Information Update: 11 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ILEX Oncology Inc
  • Class Antineoplastics; Indoles; Pyridines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Cancer metastases; Solid tumours

Most Recent Events

  • 27 Aug 2018 Genzyme completes a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Canada (IV-infusion) (NCT00003713)
  • 17 Jun 2002 Discontinued - Phase-I for Cancer metastases in USA (IV-infusion)
  • 17 Jun 2002 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top